ABSTRACT
Objective To evaluate the clinical efficacy of modified Angelica Fritilaria Sophorae Pill assisting transcatheter arterial chemoembolization (TACE) to treat primary liver cancer. Methods Totally 84 patients with primary liver cancer were randomized into combination treatment group (42 cases) and conventional control group (42 cases). The conventional control group received TACE treatment, the combination treatment group received modified Angelica Fritilaria Sophorae Decoction and TACE. The tumor volume, TCM syndrome score, life quality, immune function and toxicity reaction of both groups were observed. Results Clinical observation was completed with 37 patients in each group. After three courses of treatment, the objective tumor response rate was 91.9% in combination treatment group and 86.4% in conventional control group (P<0.05). The clinical symptoms (fever, abdominal pain, vomiting, fatigue) in both groups were improved (P<0.05), with significant difference between the two groups (P<0.05). After treatment, KPS scores increased (P<0.05) in combination treatment group, and the scores of combination treatment group were significantly higher than those of the conventional control group (P<0.05). After treatment, Th1 function level increased (P<0.05) in combination treatment group, and that was better than the conventional control group (P<0.05). The incidence of liver toxicity and gastrointestinal reaction in the combination treatment group was significantly lower than that in the conventional control group (P<0.05). Conclusion Modified Angelica Fritilaria Sophorae Pill can enhance the efficacy of TACE treatment to treat primary liver cancer, reduce adverse reactions, and improve life quality of patients with primary liver cancer.